In the biotechnology world, the sun rises and set around the two key words “safety” and “efficacy.”  A serious safety concern resulted in Bristol-Myers Squibb (NYSE: BMY) voluntarily halting its ongoing Phase 2 study of BMS-986094, a drug in development as a new indication for hepatitis C as part of the drug maker’s quest for an all-oral regimen for hep C.  A patient who had received a 200 milligram dose of the nucleotide polymerase inhibitor, or “nuke,” suffered heart failure; causing Bristol to stop the trial and begin evaluating participants to determine Read More

Expanding its footprint in the cancer treatment space, Access Pharmaceuticals, Inc. (OTCBB: ACCP) said today that Memorial Sloan-Kettering Cancer Center (MSKCC), one of the world’s premier cancer centers, has added MuGard to its cancer supportive care pharmacy formulary.  Patients undergoing cancer treatment will now have direct access to MuGard from the first day of cancer treatment to manage oral mucositis, Read More

San Diego, California-based Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Tokyo-based Astelllas Pharma Inc. (Pink Sheets: ALPMY, Tokyo: 4503) reported this morning that the execution of an exclusive collaboration and license agreement to develop and commercialize fidaxomicin tablets in Japan for the treatment of Clostridium difficile Infection (CDI). Read More

Aiming to reposition as the patent cliff is coming for many companies to lose their hold on blockbuster drugs, Merck & Co. (NYSE:MRK) said this morning that it has formed a joint venture with Supera Farma Laboratorios S.A., a Brazilian pharmaceutical company, to market, distribute and sell generic drugs in Brazil.  The new JV company will sell Read More

Swiss drug maker Novartis AG (NYSE:NVS) said this morning that it received a Complete Response letter from the U.S. Food and Drug Administration requesting more information of the use of its meningitis vaccine Menveo in infants; possibly causing a delay in its extended use in the United States. Read More

Looking to compete in the $20 billion hepatitis C drug market, Bristol-Myers Squibb (NYSE:BMY) said this weekend that it will pay roughly $2.5 billion in cash to acquire Inhibitex Inc. (NASDAQ:INHX).  This is the second major Hep-C related acquisition in as many months Read More

Access Pharmaceuticals, Inc. (OTCBB:ACCP) announced it has entered into an agreement with a major player in RNAi industry to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi (Ribonucleic acid interference) therapeutics. Access will provide the pharmaceutical company with CobOral and CobaCyte siRNA formulations for evaluation of gene knockdown following oral and intravenous administration. Access indicated that any successful formulation developed will be jointly owned by the Parties and subject to a subsequent full licensing agreement.

Phillip Wise, VP Business Development and Strategy, Access Pharmaceuticals, Inc., stated,

We are pleased to have signed an agreement with another major player in RNAi therapeutics as it continues to validate the advances in both our CobOral and CobaCyte technology platforms.  We believe the distinct advantages our CobOral and CobaCyte technologies offers is well-suited for the company’s RNAi products and we look forward to the collaborative work ahead.

Access’ CobOral and CobaCyte delivery technologies, which are based on vitamin B12, are particularly well-suited for this purpose. Most human cells have a requirement for vitamin B12 which is served by cell surface receptors which facilitate absorption of this vitamin. In many diseases, the demand for vitamin B12 is increased, with a corresponding upregulation of the receptor. Using the ‘Trojan Horse’ principle, the CobaCyte nanoparticle technology can utilize the vitamin B12 uptake mechanism to transport siRNA into cells whereupon native siRNA can be released for incorporation in messenger RNA (mRNA) to initiate the beneficial therapeutic effect. In this way, CobaCyte offers the potential for targeted delivery of siRNA following intravenous administration. The fact that Access’ vitamin B12 technology also facilitates oral drug delivery (the CobOral technology) indicates that it may also be possible for this technology to provide effective siRNA treatments by oral drug delivery.

Access Pharmaceuticals (ACCP) Stock Quote and News:

Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/?page_id=190.

ALDA Pharmaceuticals Corp. (OTCQB:APCSF, TSX-Venture:APH), a Vancouver, British Columbia-based healthcare company focused on the development of infection-control therapeutics derived from its patented T36® technology, announced the issuance of Natural Product Number (“NPN”) 80026033 for a 0.5% hydrocortisone (0.5% HC) ointment.  This is pertinent as ALDA is authorized to sell this product in Canada for temporary relief of, amongst other things, minor skin irritations, rashes, itching and redness due to eczema, insect bites, poison ivy, contact dermatitis, seborrheic dermatitis and psoriasis. U.S. traded shares have not moved today, but Toronto Venture Exchange traded shares have risen by 33.3 percent on strong volume.

More on ALDA can be found at www.aldacorp.com.

ALDA Pharmaceuticals (APCSF) Stock Quote and News:

Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/?page_id=190.

Shares of BioCurex, Inc. (OTCBB:BOCX) are up more than 100 percent on news of a completed study evaluating BioCurex’s RECAF™ performance in distinguishing benign prostate hyperplasia and prostate cancer. Results showed RECAF outperforming the conventional free-PSA (Prostate Specific Antigen) by six-fold in recognition and prevention of unnecessary prostate biopsies. More than 8 million shares have been traded less than 1 hour into the trading day, a massive increase over the 3-month average trading volume of 102,000 shares each day. To learn more, read the full press release and get a BOCX stock quote.

Access Pharmaceuticals (OTCBB:ACCP) continues to expand its global footprint for its MuGard product as an indication for oral mucositis, a common side effect of cancer therapies. The Company announced that it has received an acceptance letter from Chinese State Food and Drug Administration recognizing that all required documentation has been submitted and accepted in moving towards marketing approval. Read the full press release and get an ACCP stock quote.